drugset / Trial / NCT00527072

PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept

NCT00527072

Phase 3 Completed 217 enrolled Centocor Ortho Biotech Services, L.L.C.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months, without enough improvement in their psoriasis symptoms.

Timeline

Start
2007-07
Primary completion
2009-05
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 5 mg/kg Intravenous

Indications